Chargement en cours...

The Antitumor Drug LB-100 is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active Site Catalytic Metals in PPP5C

LB-100 is an experimental cancer-therapeutic with cytotoxic activity against cancer cells in culture and antitumor activity in animals. The first Phase I trial (NCT01837667) evaluating LB-100 recently concluded that safety and efficacy parameters are favorable for further clinical testing. Although...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Cancer Ther
Auteurs principaux: D’Arcy, Brandon M., Swingle, Mark R., Papke, Cinta M., Abney, Kevin A., Bouska, Erin S., Prakash, Aishwarya, Honkanen, Richard E.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6397705/
https://ncbi.nlm.nih.gov/pubmed/30679389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1143
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!